The two largest health insurers in Massachusetts are effectively telling the drug companies that they may seek a rapidly ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Josephs joins forces with LifeRx.md to redefine health through doctor-led GLP‑1 wellness programs—merging celeb credibility ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.

The country’s Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, the UK’s official system for ...

A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...

GLP-1 weight loss patches are everywhere but do they actually work as these trendy patches promise Ozempic-like results ...